MedTrace Logo

Fecal Microbiota Transplant (FMT) Capsule for Improving the Efficacy of GI-aGVHD

NCT05094765 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2021-10-26

No results posted yet for this study

Summary

This study aims to determine whether the fecal microbiota transplant (FMT) capsule improves the response rate of GI-aGVHD in patients with glucocorticoid-refractory acute graft vs. host disease after allogeneic stem cell transplantation

Conditions

Interventions

BIOLOGICAL

FMT

Fecal Microbiota Transplantation

Sponsors & Collaborators

  • Shenzhen Xbiome Biotech Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-01
Primary Completion
2023-03-02
Completion
2023-03-02

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05094765 on ClinicalTrials.gov